Javier Corral
About Javier Corral
Javier Corral is the Innovative Medicines Business Unit Director for Spain & Portugal at Bristol-Myers Squibb, with over 20 years of experience in sales and marketing across global, regional, and local positions.
Current Role at Bristol-Myers Squibb
Javier Corral currently serves as the Innovative Medicines Business Unit Director for Spain and Portugal at Bristol-Myers Squibb, based in Madrid. In this role, he oversees strategy and operations for developing and marketing innovative medicines in these regions. His responsibilities include managing strategic priorities for various brands and establishing relationships with key customers.
Previous Positions at Bristol-Myers Squibb
Before his current role, Javier Corral served as the Commercial Strategy & Operations Director for Spain and Portugal at Bristol-Myers Squibb from 2015 to 2018. During his tenure, he focused on aligning commercial strategies with operational activities to drive business growth in these markets.
Career at Eli Lilly and Company
Javier Corral held multiple significant positions at Eli Lilly and Company. From 2012 to 2015, he led as the European Men's Health & Osteoporosis Marketing Community Leader. Prior to that, he was the Sr. Director of Marketing & Transformation from 2008 to 2012, Business Unit Director from 2001 to 2008, and Global Marketing Manager for Oncology from 1998 to 2000. In these roles, he developed a strong background in pharmaceutical marketing and strategic business management.
Educational Background
Javier Corral holds a Master of Business Administration (MBA) and a Senior Executive MBA from IESE Business School - University of Navarra. He also achieved a Doctor of Medicine (M.D.) from Universidad de Navarra. These educational qualifications have equipped him with a robust foundation in both medical and business fields.
Experience in Sales and Marketing
With over 20 years in Sales & Marketing, Javier Corral has held various global, regional, and local positions. He has extensive experience managing portfolio investments and navigating complex market dynamics. He has a proven track record in launching new products and transforming the pharmaceutical industry at both European and global levels.